Published on January 27, 2010 at 4:42 AM
Jubilant Biosys
Ltd., a subsidiary of Jubilant Organosys Ltd., and Endo Pharmaceuticals
( ENDP)., of Chadds Ford, Pa., U.S.A., announced today that they have
expanded their drug discovery partnership in oncology, following the
successful delivery of an early stage milestone.
The year-old partnership focuses on Jubilant delivering preclinical
candidates in the therapeutic area of oncology. Endo owns the late-stage
development and commercialization rights for molecules discovered in the
partnership. Jubilant derives research funding and success-based development
and commercialization milestones.
Commenting on this development, Sri Mosur, CEO & President, Global Drug
Discovery & Development said: "We are pleased that we could deliver early
success to the discovery portfolio efforts at Endo Pharmaceuticals and this
expansion is a testimony to Jubilant's focus in building world class oncology
capabilities, among other therapeutic areas. This collaboration further
reinforces the concept of globally leveraged R&D that creates a platform for
scientists from Endo and Jubilant to collaborate in finding affordable
remedies for cancer patients worldwide."
"We have been impressed by the quality of the science and the progress
made to date by the Jubilant team on our ongoing oncology discovery program,
said Dr. Ivan Gergel, M.D, Executive Vice President of R&D at Endo
Pharmaceuticals. "Expanding our relationship in this important therapeutic
area is consistent with our strategy of building Endo's pipeline using a
virtual discovery approach, in conjunction with our in-licensing efforts."
SOURCE Jubilant Biosys Ltd